GSK plc (GSK) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Lose.
20/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 3 wins, 9 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseGSK / S&P -4.15% / 15.20% |
LoseGSK / S&P GSK unavailable / 15.00% |
LoseGSK / S&P GSK unavailable / 50.40% |
| 2026-Q11/3 |
WinGSK / S&P 13.45% / -4.33% |
LoseGSK / S&P GSK unavailable / 11.30% |
LoseGSK / S&P GSK unavailable / 27.70% |
| 2025-Q41/3 |
WinGSK / S&P 14.62% / 2.65% |
LoseGSK / S&P GSK unavailable / 9.00% |
LoseGSK / S&P GSK unavailable / 13.40% |
| 2025-Q31/3 |
WinGSK / S&P 13.64% / 8.12% |
LoseGSK / S&P GSK unavailable / 4.61% |
LoseGSK / S&P GSK unavailable / 13.45% |
| 2025-Q20/3 |
LoseGSK / S&P 0.27% / 10.94% |
LoseGSK / S&P GSK unavailable / 4.83% |
LoseGSK / S&P GSK unavailable / 10.63% |
| 2025-Q11/3 |
WinGSK / S&P 15.80% / -4.27% |
LoseGSK / S&P GSK unavailable / 4.98% |
LoseGSK / S&P GSK unavailable / 10.57% |
| 2024-Q40/3 |
LoseGSK / S&P -16.32% / 2.41% |
LoseGSK / S&P GSK unavailable / 5.25% |
LoseGSK / S&P GSK unavailable / 6.15% |
| 2024-Q31/3 |
WinGSK / S&P 7.18% / 5.89% |
LoseGSK / S&P GSK unavailable / 5.89% |
LoseGSK / S&P GSK unavailable / 6.11% |
| 2024-Q20/3 |
LoseGSK / S&P -9.45% / 4.28% |
LoseGSK / S&P GSK unavailable / 5.38% |
LoseGSK / S&P GSK unavailable / 5.12% |
| 2024-Q11/3 |
WinGSK / S&P 16.81% / 10.56% |
LoseGSK / S&P GSK unavailable / 5.71% |
LoseGSK / S&P GSK unavailable / 5.59% |
| 2023-Q40/3 |
LoseGSK / S&P 3.25% / 11.69% |
LoseGSK / S&P GSK unavailable / 6.81% |
LoseGSK / S&P GSK unavailable / 7.78% |
| 2023-Q31/3 |
WinGSK / S&P 2.77% / -3.27% |
LoseGSK / S&P GSK unavailable / 7.52% |
LoseGSK / S&P GSK unavailable / -5.03% |
| 2023-Q20/3 |
LoseGSK / S&P 1.14% / 8.74% |
LoseGSK / S&P GSK unavailable / 9.50% |
LoseGSK / S&P GSK unavailable / -8.57% |
| 2023-Q10/3 |
LoseGSK / S&P 2.22% / 7.50% |
LoseGSK / S&P GSK unavailable / 10.77% |
LoseGSK / S&P GSK unavailable / -15.69% |
| 2022-Q41/3 |
WinGSK / S&P 20.56% / 7.56% |
LoseGSK / S&P GSK unavailable / 11.88% |
LoseGSK / S&P GSK unavailable / -17.99% |
| 2022-Q30/3 |
LoseGSK / S&P -31.62% / -4.88% |
LoseGSK / S&P GSK unavailable / 13.47% |
LoseGSK / S&P GSK unavailable / -1.41% |
| 2022-Q21/3 |
WinGSK / S&P 0.74% / -16.10% |
LoseGSK / S&P GSK unavailable / 13.71% |
LoseGSK / S&P GSK unavailable / 11.04% |
| 2022-Q11/3 |
WinGSK / S&P 0.22% / -4.60% |
LoseGSK / S&P GSK unavailable / 15.97% |
LoseGSK / S&P GSK unavailable / 42.23% |
| 2021-Q41/3 |
WinGSK / S&P 16.85% / 11.03% |
LoseGSK / S&P GSK unavailable / 15.00% |
LoseGSK / S&P GSK unavailable / 96.40% |
| 2021-Q30/3 |
LoseGSK / S&P -2.82% / 0.58% |
LoseGSK / S&P GSK unavailable / 10.77% |
LoseGSK / S&P GSK unavailable / 69.42% |
| 2021-Q21/3 |
WinGSK / S&P 13.09% / 8.55% |
LoseGSK / S&P GSK unavailable / 6.58% |
LoseGSK / S&P GSK unavailable / 51.81% |
| 2021-Q10/3 |
LoseGSK / S&P -1.29% / 6.17% |
LoseGSK / S&P GSK unavailable / -1.06% |
LoseGSK / S&P GSK unavailable / 7.39% |
| 2020-Q40/3 |
LoseGSK / S&P -0.98% / 12.15% |
LoseGSK / S&P GSK unavailable / -3.72% |
LoseGSK / S&P GSK unavailable / -33.42% |
| 2020-Q30/3 |
LoseGSK / S&P -6.64% / 8.93% |
LoseGSK / S&P GSK unavailable / -2.04% |
LoseGSK / S&P GSK unavailable / -27.10% |
| 2020-Q20/3 |
LoseGSK / S&P 8.86% / 20.54% |
LoseGSK / S&P GSK unavailable / -0.46% |
LoseGSK / S&P GSK unavailable / -27.11% |
| 2020-Q11/3 |
WinGSK / S&P -18.24% / -19.60% |
LoseGSK / S&P GSK unavailable / 3.47% |
LoseGSK / S&P GSK unavailable / -14.75% |
| 2019-Q41/3 |
WinGSK / S&P 11.32% / 9.07% |
LoseGSK / S&P GSK unavailable / 5.36% |
LoseGSK / S&P GSK unavailable / 2.99% |
| 2019-Q31/3 |
WinGSK / S&P 7.88% / 1.70% |
LoseGSK / S&P GSK unavailable / 5.02% |
LoseGSK / S&P GSK unavailable / 0.21% |
| 2019-Q20/3 |
LoseGSK / S&P -3.02% / 4.30% |
LoseGSK / S&P GSK unavailable / 6.64% |
LoseGSK / S&P GSK unavailable / 8.65% |
| 2019-Q10/3 |
LoseGSK / S&P 10.97% / 13.65% |
LoseGSK / S&P GSK unavailable / 8.12% |
LoseGSK / S&P GSK unavailable / 14.29% |
| 2018-Q41/3 |
WinGSK / S&P -3.72% / -13.52% |
LoseGSK / S&P GSK unavailable / 9.05% |
LoseGSK / S&P GSK unavailable / 18.23% |
| 2018-Q30/3 |
LoseGSK / S&P 0.87% / 7.71% |
LoseGSK / S&P GSK unavailable / 10.21% |
LoseGSK / S&P GSK unavailable / 19.06% |
| 2018-Q21/3 |
WinGSK / S&P 4.55% / 3.43% |
LoseGSK / S&P GSK unavailable / 9.03% |
LoseGSK / S&P GSK unavailable / 14.46% |
| 2018-Q11/3 |
WinGSK / S&P 12.07% / -0.76% |
LoseGSK / S&P GSK unavailable / 7.68% |
LoseGSK / S&P GSK unavailable / 12.46% |
| 2017-Q40/3 |
LoseGSK / S&P -11.41% / 6.64% |
LoseGSK / S&P GSK unavailable / 7.03% |
LoseGSK / S&P GSK unavailable / 13.82% |
| 2017-Q30/3 |
LoseGSK / S&P -4.67% / 4.48% |
LoseGSK / S&P GSK unavailable / 5.68% |
LoseGSK / S&P GSK unavailable / 17.57% |
| 2017-Q21/3 |
WinGSK / S&P 3.48% / 3.09% |
LoseGSK / S&P GSK unavailable / 4.83% |
LoseGSK / S&P GSK unavailable / 17.74% |
| 2017-Q11/3 |
WinGSK / S&P 11.01% / 6.07% |
LoseGSK / S&P GSK unavailable / 3.67% |
LoseGSK / S&P GSK unavailable / 13.32% |
| 2016-Q40/3 |
LoseGSK / S&P -9.66% / 3.82% |
LoseGSK / S&P GSK unavailable / 2.09% |
LoseGSK / S&P GSK unavailable / 7.05% |
| 2016-Q30/3 |
LoseGSK / S&P 0.65% / 3.85% |
LoseGSK / S&P GSK unavailable / 0.20% |
LoseGSK / S&P GSK unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | GSK total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 31.21% | 20.78% |
| Annualized return | 31.21% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | GSK total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 49.71% | 83.14% |
| Annualized return | 8.41% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | GSK total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 85.96% | 319.30% |
| Annualized return | 6.40% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.